- Home
- Publications
- Publication Search
- Publication Details
Title
The safety of daclatasvir for the treatment of hepatitis C
Authors
Keywords
-
Journal
Expert Opinion On Drug Safety
Volume 14, Issue 11, Pages 1787-1797
Publisher
Informa Healthcare
Online
2015-11-17
DOI
10.1517/14740338.2015.1100603
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study
- (2015) David R. Nelson et al. HEPATOLOGY
- Daclatasvir in Combination With Asunaprevir and Beclabuvir for Hepatitis C Virus Genotype 1 Infection With Compensated Cirrhosis
- (2015) Andrew J. Muir et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Fixed-Dose Combination Therapy With Daclatasvir, Asunaprevir, and Beclabuvir for Noncirrhotic Patients With HCV Genotype 1 Infection
- (2015) Fred Poordad et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Comparison of Daclatasvir Resistance Barriers on NS5A from Hepatitis C Virus Genotypes 1 to 6: Implications for Cross-Genotype Activity
- (2014) Chunfu Wang et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Daclatasvir + Asunaprevir: First Global Approval
- (2014) Raewyn M. Poole DRUGS
- New Hepatitis C Therapies: The Toolbox, Strategies, and Challenges
- (2014) Jean–Michel Pawlotsky GASTROENTEROLOGY
- Daclatasvir-Like Inhibitors of NS5A Block Early Biogenesis of Hepatitis C Virus–Induced Membranous Replication Factories, Independent of RNA Replication
- (2014) Carola Berger et al. GASTROENTEROLOGY
- Kinetic Analyses Reveal Potent and Early Blockade of Hepatitis C Virus Assembly by NS5A Inhibitors
- (2014) David R. McGivern et al. GASTROENTEROLOGY
- Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection
- (2014) Hiromitsu Kumada et al. HEPATOLOGY
- Retreatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin
- (2014) Stefan Zeuzem et al. NEW ENGLAND JOURNAL OF MEDICINE
- Treatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin
- (2014) Jordan J. Feld et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection
- (2014) Nezam Afdhal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 Infection
- (2014) Nezam Afdhal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis
- (2014) Kris V. Kowdley et al. NEW ENGLAND JOURNAL OF MEDICINE
- ABT-450/r–Ombitasvir and Dasabuvir with or without Ribavirin for HCV
- (2014) Peter Ferenci et al. NEW ENGLAND JOURNAL OF MEDICINE
- Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV Infection
- (2014) Mark S. Sulkowski et al. NEW ENGLAND JOURNAL OF MEDICINE
- ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with Cirrhosis
- (2014) Fred Poordad et al. NEW ENGLAND JOURNAL OF MEDICINE
- Persistence of Resistant Variants in Hepatitis C Virus-Infected Patients Treated with the NS5A Replication Complex Inhibitor Daclatasvir
- (2013) Chunfu Wang et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Assessment of pharmacokinetic interactions of the HCV NS5A replication complex inhibitor daclatasvir with antiretroviral agents: ritonavir-boosted atazanavir, efavirenz and tenofovir.
- (2013) Marc Bifano et al. ANTIVIRAL THERAPY
- Effect of the coadministration of daclatasvir on the pharmacokinetics of a combined oral contraceptive containing ethinyl estradiol and norgestimate
- (2013) Marc Bifano et al. ANTIVIRAL THERAPY
- Review of direct-acting antiviral agents for the treatment of chronic hepatitis C
- (2013) Nihar Shah et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Selection of Resistant–Associated Variants to the NS5A Inhibitor Daclatasvir: Revenge of the Hepatitis C Virus
- (2013) Alessio Aghemo et al. GASTROENTEROLOGY
- Resistance analysis of hepatitis C virus genotype 1 prior treatment null responders receiving daclatasvir and asunaprevir
- (2013) Fiona McPhee et al. HEPATOLOGY
- Modelling clinical data shows active tissue concentration of daclatasvir is 10-fold lower than its plasma concentration
- (2013) R. Ke et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- 1203 SAFETY PROFILE OF DACLATASVIR IN COMBINATION WITH PEGINTERFERON alfa AND RIBAVIRIN IN 1100 PATIENTS WITH CHRONIC HCV INFECTION TREATED IN PHASE 2 STUDIES
- (2013) I. Jacobson et al. JOURNAL OF HEPATOLOGY
- 1413 SIMEPREVIR (TMC435) WITH PEGINTERFERON/RIBAVIRIN FOR TREATMENT OF CHRONIC HCV GENOTYPE-1 INFECTION IN TREATMENT-NAÏVE PATIENTS: RESULTS FROM QUEST-2, A PHASE III TRIAL
- (2013) M. Manns et al. JOURNAL OF HEPATOLOGY
- 1425 SIMEPREVIR (TMC435) WITH PEGINTERFERON/RIBAVIRIN FOR CHRONIC HCV GENOTYPE-1 INFECTION IN TREATMENT-NAÏVE PATIENTS: RESULTS FROM QUEST-1, A PHASE III TRIAL
- (2013) I. Jacobson et al. JOURNAL OF HEPATOLOGY
- Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders
- (2013) Anna S. Lok et al. JOURNAL OF HEPATOLOGY
- Interferon free therapy with direct acting antivirals for HCV
- (2013) Tarik Asselah et al. LIVER INTERNATIONAL
- HCV direct-acting antiviral agents: the best interferon-free combinations
- (2013) Raymond Schinazi et al. LIVER INTERNATIONAL
- Global epidemiology of hepatitis C virus infection: New estimates of age-specific antibody to HCV seroprevalence
- (2012) Khayriyyah Mohd Hanafiah et al. HEPATOLOGY
- Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir
- (2012) Yoshiyasu Karino et al. JOURNAL OF HEPATOLOGY
- Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options
- (2012) Yoshiyuki Suzuki et al. JOURNAL OF HEPATOLOGY
- Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial
- (2012) Stanislas Pol et al. LANCET INFECTIOUS DISEASES
- Small molecule inhibitors of the hepatitis C virus-encoded NS5A protein
- (2012) Oscar Belda et al. VIRUS RESEARCH
- Multiple ascending dose study of BMS-790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1
- (2011) Richard E. Nettles et al. HEPATOLOGY
- Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in Humans: In Vitro and In Vivo Correlations
- (2011) Robert A. Fridell et al. HEPATOLOGY
- Distinct Functions of NS5A in Hepatitis C Virus RNA Replication Uncovered by Studies with the NS5A Inhibitor BMS-790052
- (2011) R. A. Fridell et al. JOURNAL OF VIROLOGY
- A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt
- (2011) William Sievert et al. LIVER INTERNATIONAL
- The global health burden of hepatitis C virus infection
- (2011) Francesco Negro et al. LIVER INTERNATIONAL
- A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel
- (2011) Markus Cornberg et al. LIVER INTERNATIONAL
- Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection
- (2011) Ira M. Jacobson et al. NEW ENGLAND JOURNAL OF MEDICINE
- The hepatitis C virus NS5A inhibitor (BMS-790052) alters the subcellular localization of the NS5A non-structural viral protein
- (2011) Choongho Lee et al. VIROLOGY
- Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect
- (2010) Min Gao et al. NATURE
- Review: New direct-acting antivirals in the development for hepatitis C virus infection
- (2010) Paul J. Pockros Therapeutic Advances in Gastroenterology
- Synthesis and SAR of piperazinyl-N-phenylbenzamides as inhibitors of hepatitis C virus RNA replication in cell culture
- (2009) Immacolata Conte et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Diagnosis, management, and treatment of hepatitis C: An update
- (2008) Marc G. Ghany et al. HEPATOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started